Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line

Nabeta, Yuki; Kawaguchi, Satoshi; Sahara, Hiroeki; Ikeda, Hideyuki; Hirohashi, Yoshihiko; Goroku, Takahiro; Satō, Yoshihiro; Tsukahara, Tomohide; Torigoe, Toshihiko; Wada, Takuro; Kaya, Mitsunori; Hiraga, Hiroaki; Isu, Kazuo; Yamawaki, Shinya; Ishii, Seiichi; Yamashita, Toshihiko; Sato, Noriyuki

doi:10.1007/s00776-003-0663-5

Cited by 30 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OS2000, KIKU and MFH2003 were established in our laboratory (Wada et al, 1988;Nabeta et al, 2003;Tsukahara et al, 2006). The other cell lines were kindly donated by or purchased from the Japanese Collection of Research Bioresources Cell Bank (Tokyo, Japan) and from the American Type Culture Collection (Manassas, VA, USA).…”

Section: Cell Lines and Culturementioning

confidence: 99%

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: Several human cancers have been found to contain cancer stem-like cells (CSCs) having cancer-initiating ability. However, only a few reports have shown the existence of CSCs in bone and soft tissue sarcomas. In this study, we identified and characterised side population (SP) cells that showed drug-resistant features in human bone sarcoma cell lines. METHODS: In seven osteosarcoma cell lines (OS2000, KIKU, NY, Huo9, HOS, U2OS and Saos2) and in one bone malignant fibrous histiocytoma (MFH) cell line (MFH2003), the frequency of SP cells was analysed. Tumourigenicity of SP cells was assessed in vitro and in vivo. Gene profiles of SP cells and other populations (main population; MP) of cells were characterised using cDNA microarrays. RESULTS: SP cells were found in NY (0.31%) and MFH2003 (5.28%). SP cells of MFH2003 formed spherical colonies and re-populated into SP and MP cells. In an NOD/SCID mice xenograft model, 1 Â 10 3 sorted SP cell-induced tumourigenesis. cDNA microarray analysis showed that 23 genes were upregulated in SP cells. CONCLUSIONS: We showed that SP cells existed in bone sarcoma cell lines. SP cells of MFH2003 had cancer-initiating ability in vitro and in vivo. The gene profiles of SP cells could serve as candidate markers for CSCs in bone sarcomas.

show abstract

Section: Cell Lines and Culturementioning

confidence: 99%

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…With the goal of identifying efficacious therapeutic antigens in bone and soft tissue sarcomas, we have conducted a series of studies with the strategies referred to as forward immunology 16,17,21 and reverse immunology. 19,20 The present study was designed with the forward immunology strategy, which is based on the establishment of an autologous pair of tumor cells and tumor cellreactive CTLs.…”

Section: Discussionmentioning

confidence: 99%

“…Epstein-Barr virus-transformed B cells were also established from a blood sample of the same patient and designated B2004-EBV according to a method described previously. 16,17 Xenotransplantation Model MFH2004 cells (2 Â 10 7 ) were injected subcutaneously into the backs of three 6-week-old NOD-SCID mice (NOD.CB17.prdkc scid /J, The Jackson Laboratory, Bar Harbor, ME). On day 30, the tumor was resected and fixed in formalin.…”

Section: Establishment Of Cell Linesmentioning

confidence: 99%

Clonal T‐cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA‐A*0206

Kimura

Kozakai

Kawaguchi

et al. 2007

Journal Orthopaedic Research

Self Cite

View full text Add to dashboard Cite

Towards the goal of identifying tumor-rejection antigens on eradicated tumors in bone and soft tissue sarcomas, we evaluated the immune response against antigens presented by lost HLA class I molecules. Tumor specimens and peripheral blood samples were obtained from a 70-year-old woman with pleomorphic malignant fibrous histiocytoma. Over 1-year culture, a tumor cell line (MFH2004) was established. A B-cell line infected with Epstein-Barr virus (B2004-EBV) was developed from the blood samples. HLA genotypes of B2004-EBVcells were

show abstract

“…The reasons for this delay were discussed (9,79) and the following points were raised; i) the relatively low immunogenicity of osteosarcoma as only few examples of spontaneous tumor regression exist (80,81), ii) the practical difficulty in establishing osteosarcoma cell lines and autologous CTL (82,83) and iii) the lack of suitable candidate genes for a reverse immunological approach such as a tumorspecific fusion gene (84,85). However, another hopeful explanation of this delay resides in environmental factors peculiar to bone.…”

Section: Summary and Future Trendsmentioning

confidence: 99%

Osteosarcoma: Current status of immunotherapy and future trends (Review)

Mori¹,

Rédini²,

Cherrier³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most common primary bone tumor and represents a major therapeutic challenge in medical oncology. While the use of aggressive chemotherapy has drastically improved the prognosis of the patients with nonmetastatic osteosarcomas, the very poor prognosis of patients with metastasis have led to the exploration of new, more effective and less toxic treatments, such as immunotherapy for curing osteosarcoma. Compared to the numerous reports describing successful immunotherapy for other solid tumors, the number of reports concerning immunotherapy for osteosarcoma is low. However, this therapeutic strategy opens new areas for the treatment of osteosarcoma. In this review, the reasons for delay and all elements essential to develop immunotherapy concerning osteosarcoma are defined. Several pieces of evidence strongly support the potential capability of new therapies such as cellular therapy and gene therapy to eradicate osteosarcoma. Thus, clinical human trials using peptides, cytokines and dendritic cells have been performed. Tumor-infiltrating lymphocytes and some tumor antigens have been identified in osteosarcoma and resulted in an important breakthrough in cellular immunotherapy. Also, RANKL/RANK/OPG, the key regulator of bone metabolism, is a hot spot in this field as therapeutic tools. Immunotherapy for osteosarcomas has great potential, promising improvement in the survival rate and better quality of life for the patients.

show abstract

Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line

Cited by 30 publications

References 16 publications

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas

Clonal T‐cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA‐A*0206

Osteosarcoma: Current status of immunotherapy and future trends (Review)

Contact Info

Product

Resources

About